AbbVie licenses Nxera oral inflammatory bowel disease drug in agreement worth up to $1.47 billion
AbbVie has secured exclusive worldwide rights to Nxera Pharma's investigational oral EP4 receptor agonist NXE0033744 for inflammatory bowel disease in a licensing agreement potentially worth $1.47 billion.
The transaction announced on 4 November 2026 provides Nxera with $100 million upfront and eligibility for up to $1.37 billion in development and commercial milestones plus tiered royalties, giving AbbVie responsibility for further development and commercialisation of the gut-targeted small molecule.
Discovered using Nxera's NxWave platform, NXE0033744 has completed Phase I studies including evaluation in a cohort with ulcerative colitis, but remains investigational, while completion of the licensing transaction is subject to customary antitrust clearance.
Field | Content |
Article Type | Deals |
Company | AbbVie |
Licensing Partner | Nxera Pharma |
Deal Type | Exclusive worldwide licence agreement |
Announcement Date | 4 November 2026 |
Transaction Status | Announced; subject to customary antitrust clearance |
Licensed Asset | NXE0033744 |
Drug Class | EP4 receptor agonist |
Modality | Oral small-molecule therapeutic |
Administration Route | Oral |
Therapeutic Area | Gastroenterology; inflammatory bowel disease |
Target Indication | Inflammatory bowel disease |
Clinical Population Studied | Phase I programme included a cohort with ulcerative colitis |
Development Stage | Phase I completed |
Discovery Platform | Nxera NxWave |
Drug Design Focus | Gut-targeted EP4 receptor agonism |
Maximum Potential Deal Value | $1.47 billion excluding royalties |
Upfront Payment | $100 million |
Potential Milestone Payments | Up to $1.37 billion |
Milestone Categories | Development and commercial |
Royalty Structure | Tiered royalties; rates not specified in supplied summary |
Development Rights | AbbVie receives worldwide development rights |
Commercialisation Rights | AbbVie receives worldwide commercialisation rights |
Geographic Scope | Worldwide |
Regulatory Status | Investigational; not approved |
Transaction Conditions | Customary antitrust clearance |
What Happened | AbbVie entered an exclusive global licence agreement for Nxera's investigational EP4 receptor agonist NXE0033744. |
Why It Matters | The agreement adds a differentiated oral inflammatory bowel disease candidate to AbbVie's development pipeline and validates Nxera's discovery platform through a major pharmaceutical partnership. |
Strategic Rationale | Advance a gut-targeted oral therapeutic for inflammatory bowel disease using AbbVie's global clinical development and commercial capabilities. |
Financial Clarification | The $1.47 billion potential value comprises $100 million upfront and up to $1.37 billion in contingent milestones, excluding royalties. |
Key Takeaway | AbbVie has agreed to license a Phase I-completed investigational IBD candidate with significant milestone-based consideration. |
What to Watch | Antitrust clearance, subsequent clinical development, efficacy and safety results, regulatory submissions and milestone payments. |
Primary Source | Nxera Pharma |
Primary Source URL | https://rss.globenewswire.com/news-release/2026/11/04/3395033/0/en/nxera-pharma-enters-into-global-license-agreement-with-abbvie-for-nxe0033744-a-novel-ep4-receptor-agonist-for-inflammatory-bowel-disease.html |
Relevant Date | 4 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti